Mon, Jul 28, 2014, 11:52 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Boston Scientific Corporation Message Board

  • runesigns runesigns Feb 26, 1999 4:08 PM Flag

    Coverage initiated - stock holds it own

    http://biz.yahoo.com/c/99/02/26/u.html#i
    ...Schroeder and Co initiates coverage with perform in-line
    (with expectations).

    ...What is interesting is
    that there has been about 100K+ shares being bought in
    the last minutes of trading the last two days and
    today. Today the stock recovered nicely with good volume
    after sell-offs with low volume. On balance volume
    shows an increase of 600k shares over the last two days
    even though the price is unchanged over that
    time.

    ...Definitely looks as though someone is trying to quitely
    accumulate the stock. I don't know Schroeder and Co but it
    is not uncommon for analyst to downplay a stock
    while they accumulate. (Or conversely, to upgrade a
    stock before dumping - look at AMAT over the last
    week!).

    ...If the overall market can settle down I think we
    will be looking at 30+ soon.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't think what you said is legal. What you
      follows:

      Definitely looks as though someone is trying to quitely
      accumulate the stock. I don't know Schroeder and Co but it
      is not uncommon for analyst to downplay a stock
      while they accumulate. (Or conversely, to upgrade a
      stock before dumping - look at AMAT over the last
      week!).

      Anyone else have an opinion about this?

    • You're right, it does on the face of it seem
      strange - but in this case they are not taking advantage
      of the self-expanding features of nitinol for the
      Paragon stent. For a start, self-expanding stents haven't
      worked out well in coronary applications. In this case
      the stent is made out of nitinol because of potential
      patent infringement problems. Stainless steel - which
      all the other approved coronary stents are made of,
      undergoes plastic deformation upon expansion, thus
      potentially falling within the scope of J&J's Palmaz patent
      (allegedly). Nitinol does not - so this was the rationale
      behind developing a balloon expandable nitinol stent.
      You'll have to talk to a metallurgist if you want more
      detail, but the bottom line is the patent situation. So
      all the balloon expandable stainless steel stent
      players in the US are currently being sued by J&J - but
      that's another story which we'll have to wait to see
      unfold.
      The interventional cardiology area is a patent
      minefield and a good industry for lawyers to make a lot of
      money out of.
      Hope that clears up your question
      Ang.
      Woody

    • Boston Scientific will be selling the urology portion of their business to Abbott, not the whole, just a part.

    • I heard of a new product soon to be released. Does the beez or cjoe know of it and what it's for. I think it's called OASIS. Will it be an inpact? Sorry for the limited info

    • You are unbelievably brilliant! Will you do all my investing for me and come to Vail to teach me ski as well as you?

    • preying J&J and/or MDT take over of BSX is just
      what the BSX folks hated. Look at the two, both made
      major acquisition in their istory into the VI business,
      and both made big fool of themselves. So, if you
      really care about your investment in BSX, you don't want
      to hold the converted J&J or MDT.

      BTW, Nir is
      not the best stent on market. It is so stiff, and not
      visible. Put it on any catheter, viva, or sox, will not
      make it better. BSX is making the same mistake as J&J
      by sleeping on the old Nir. You can only count the
      market share of Nir going down if there is no new
      innovation (ironically from Medinol, not BSX)...

    • But check out Endosonics - their solid state IVUS
      system is gaining ground in Europe and US on BSX and
      they are about to launch a combination IVUS/stent
      delivery system. That's a step ahead of BSX, who probably
      can't achieve the same miniaturisation with their
      mechanical system. Shame Endosonics is working with the
      Jomed stent in Europe.
      If you want to check out some
      IVUS data, look at the results from the MUSIC trial
      with the Endosonics system - 10% angiographic
      restenosis at 6 months for IVUS deployed stents. That's
      better than any other published data.
      Barriers to the
      use of IVUS have been cost and also it adds time to
      the procedure - the combi system will help and should
      take further market share from BSX and also make IVUS
      more user friendly - but they need to marry a decent
      stent with it.
      I would expect one of the big three
      to acquire Endosonics in the next 12 months - most
      likely to be GDT, least likely to be BSX.
      Woody

    • If you want to be loved, make up your own
      alternate identities. Skibum created me and I'll be loyal
      to him forever. Plus it's too late, I've already
      sent him all my money.
      Also, don't waste your time
      on southcave, simply watching, htcdad, thimbo99 or
      of the other new ones our new Woodfleet is cranking
      out daily.

    • I noticed you said you havn't seen the AVE rep for 3 months. Do you have any idea as to why?

    • View More Messages
 
BSX
12.97-0.14(-1.07%)Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.